Clinical Trials Directory

Trials / Conditions / Leukemia, Myeloid, Chronic-Phase

Leukemia, Myeloid, Chronic-Phase

14 registered clinical trials studyying Leukemia, Myeloid, Chronic-Phase — 1 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingA Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patient
NCT07454850
Novartis Pharmaceuticals—
CompletedTreatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community
NCT07374120
Novartis Pharmaceuticals—
TerminatedStudy in Patients With Chronic Leukemia
NCT03807479
GWT-TUD GmbHPhase 2
UnknownImatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log
NCT03239886
University of Sao Paulo General HospitalN/A
UnknownTherapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelo
NCT02767063
Versailles HospitalPhase 1 / Phase 2
WithdrawnImatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms
NCT01650467
Centre Hospitalier Universitaire de Nīmes—
CompletedNilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells
NCT01856283
Niguarda HospitalPhase 2
CompletedSafety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leuk
NCT01725204
Norwegian University of Science and TechnologyPhase 2
TerminatedSirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants
NCT01488253
The Korean Society of Blood and Marrow TransplantationPhase 2
CompletedPioglityazone and Imatinib for CML Patients
NCT02888964
Versailles HospitalPhase 2
TerminatedPhase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Respon
NCT01827930
Institut BergoniéPhase 3
TerminatedEfficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosi
NCT00124748
Novartis PharmaceuticalsPhase 3
CompletedBMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia P
NCT00103701
Bristol-Myers SquibbPhase 1
CompletedTherapy of Early Chronic Phase CML With Gleevec
NCT00048672
M.D. Anderson Cancer CenterPhase 2